Bayer 's ( BAYRY ) HealthCare
segment recently announced that it will present data from a Xarelto
clinical program at the XXIVth Congress of the International
Society on Thrombosis and Haemostasis soon.BAYER A G -ADR (BAYRY): Free Stock Analysis
ReportJAZZ PHARMACEUT (JAZZ): Free Stock Analysis
ReportJOHNSON & JOHNS (JNJ): Free Stock Analysis
ReportNOVO-NORDISK AS (NVO): Free Stock Analysis
ReportTo read this article on Zacks.com click here.Zacks Investment
Xarelto is marketed by Johnson & Johnson ( JNJ ) in the US and by
Bayer outside the US.
Data will be presented from the pivotal EINSTEIN program which
consists of three phase III studies on Xarelto in comparison to the
dual-drug regimen of low molecular weight heparin (LMWH) and
vitamin K antagonist (VKA) in patients suffering from deep vein
thrombosis (DVT) and pulmonary embolism (PE) and the prevention of
recurrent DVT and PE. Bayer and Johnson & Johnson enrolled over
100,000 patients for the program around the world.
Results from the studies confirmed the effectiveness of Xarelto as
a monotherapy for the treatment of DVT and PE. Results further
revealed that Xarelto had a lower rate and severity of major
bleeding in comparison to dual-drug therapy of LMWH and VKA.
Xarelto was also found to be more cost-effective compared to
dual-drug therapy for treating PE and for the secondary prevention
of venous blood clots.
We note that Xarelto is already approved for several indications
in the US including stroke prevention in nonvalvular atrial
fibrillation, DVT, PE and reducing the risk of recurrent DVT and
PE. In the first quarter of 2013, Xarelto sales increased 269% year
over year to €155 million.
Bayer and Johnson & Johnson are looking to expand Xarelto's
indication further. Successful label expansion will boost the sales
potential of the drug.
However, earlier in the year, Bayer and Johnson & Johnson
received a huge setback when the US Food and Drug Administration
(FDA) issued a second complete response letter for the supplemental
New Drug Application (sNDA) for Xarelto (2.5 mg twice daily) for
the reduction of the risk of secondary cardiovascular events in
patients suffering from acute coronary syndrome.
Bayer presently carries a Zacks Rank #3 (Hold). Meanwhile, other
stocks such as Jazz Pharmaceuticals Public Ltd (
JAZZ ) and
Novo Nordisk ( NVO ) currently look
more attractive. While Jazz Pharma carries a Zacks Rank #1 (Strong
Buy), Novo Nordisk carries a Zacks Rank #2 (Buy).